Comparative Pharmacology
Head-to-head clinical analysis: IV PERSANTINE versus MINOXIDIL FOR MEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IV PERSANTINE versus MINOXIDIL FOR MEN.
IV PERSANTINE vs MINOXIDIL (FOR MEN)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits adenosine deaminase and phosphodiesterase, increasing intracellular cAMP and adenosine; causes coronary vasodilation and inhibits platelet aggregation.
Minoxidil is a direct-acting peripheral vasodilator that opens ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation. In hair follicles, it promotes hair growth by increasing blood flow, stimulating prostaglandin synthesis, and prolonging the anagen phase.
0.14 mg/kg/min intravenous infusion over 4 minutes for myocardial perfusion imaging.
Oral: 2.5-5 mg once daily; may increase to 10 mg once daily if needed. Topical: 5% solution, 1 mL applied to dry scalp twice daily; 5% foam, half a capful applied twice daily; 2% solution, 1 mL applied twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in adults; may be prolonged in patients with hepatic impairment.
Terminal half-life: 3.5-4.5 hours. Clinical context: Short half-life necessitates twice-daily dosing for hypertension; for topical use, systemic absorption is minimal so half-life less relevant.
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; renal excretion of unchanged drug is minimal (<1%); biliary/fecal elimination accounts for approximately 90% of the dose.
Renal: 85-90% (primarily unchanged drug and metabolites). Biliary/fecal: <5%.
Category C
Category A/B
Vasodilator
Vasodilator / Hair Growth Stimulant